Novo Nordisk and Eli Lilly have lifted their full‑year forecasts as demand for weight‑loss drugs soars. Novo Nordisk now expects sales and adjusted operating profit growth to stay flat or fall by up to 6%, up from a previously projected drop of 12%. In Q2 the Danish firm logged DKr78.5bn ($12.1bn) in net sales, a 3% rise on the year at constant currency, while operating profit climbed 11%. The company’s shares fell nearly 6% after the update, reflecting investor worry over its heavy reliance on GLP‑1 obesity and diabetes products.

In contrast, Eli Lilly reported a 48% jump in Q2 revenue to $23bn, driven by obesity and diabetes treatments, and raised its full‑year revenue outlook to $85bn‑$87bn from $82bn‑$85bn. Lilly’s shares rose more than 5% in pre‑market trading. Investors have noted that Lilly’s obesity and diabetes products now account for about 65% of its revenue.

Both firms face pricing pressure in the US, where the $12.1bn market has seen a 4% decline on a constant‑rate basis. Despite this, executives argue that volume growth will eventually offset lower prices. The companies remain committed to expanding their product pipelines while competing across the broader obesity‑diabetes landscape.

Overall, the industry sees a bullish outlook driven by rising demand, but investors remain cautious about over‑reliance on a narrow product base.